Comparative Pharmacology
Head-to-head clinical analysis: PROLOPRIM versus SATRIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROLOPRIM versus SATRIC.
PROLOPRIM vs SATRIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial dihydrofolate reductase (DHFR), blocking the conversion of dihydrofolic acid to tetrahydrofolic acid, thereby inhibiting bacterial DNA, RNA, and protein synthesis.
SATRIC is a combination of sulfathiazole, sulfacetamide, and sulfabenzamide, which are sulfonamide antibiotics. They competitively inhibit dihydropteroate synthase, blocking folate synthesis in susceptible bacteria.
100 mg orally twice daily or 200 mg orally once daily.
No standard dosing information available for SATRIC.
None Documented
None Documented
Terminal elimination half-life is 8-10 hours in normal renal function; prolonged (>20 hours) in significant renal impairment.
3-5 hours in healthy adults; prolonged to 6-8 hours in renal impairment (CrCl < 30 mL/min)
Primarily renal (80-90% as unchanged drug); less than 5% as metabolites; fecal excretion negligible.
Renal: 70% unchanged; fecal: 20%; biliary: 10%
Category C
Category C
Antibiotic
Antiprotozoal, Antibiotic